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We investigated relations between measured body mass index (BMI) and stature and thyroid cancer (3046 cases) in a large
Norwegian cohort of more than two million individuals. The risk of thyroid cancer, especially of the papillary and follicular types,
increased moderately with increasing BMI and height in both sexes.
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Several types of malignancies have been associated with increased
weight, as summarised recently (IARC Working Group on the
Evaluation of Cancer-Preventive Strategies, 2002). As thyroid
cancer is relatively rare, with only a few studies of its association
with obesity, the working group did not include it in its review.
In 1993–1997, thyroid cancer comprised 0.5 and 1.4% of all
male and female cancer cases, respectively, in the Nordic countries
(Møller et al, 2002). In Norway, the (world) age-adjusted incidence
rates in 2004 were 1.5 and 5.1 per 100000 persons per year in men
and women, respectively (The Cancer Registry of Norway, 2006),
the higher rates among women being typical (Parkin et al, 2005).
In the US, the rates of thyroid cancer are significantly higher and
increasing. In 2001, the age-adjusted incidence rates were 4.2 and
12 per 100000 persons per year in males and females (National
Cancer Institute, 2005).
In the present study, we used measurements from Norwegian
health surveys to examine the relations between body mass index
(BMI) and stature and the risk of thyroid cancer. We have recently
published similar analyses for a range of cancers (Engeland et al,
2003a–c, 2004, 2005; Bjørge et al, 2004).
MATERIALS AND METHODS
The study population and the methods have been described
elsewhere (Bjørge et al, 2004). In a number of Norwegian health
surveys during 1963–2001, height and weight were measured in
2001727 persons (963709 men and 1038018 women) aged 20–74
years in a standardised way by a trained staff. A major part of the
health surveys in the period 1963–1975 was included in a
nationwide tuberculosis screening programme (Waaler, 1984),
which was compulsory for all Norwegians aged 15 years and above;
attendance was about 85%. In 1963–1964 and in 1972–2001,
height and weight were also measured in other health surveys
connected with coronary heart disease in different parts of Norway
(Bjartveit et al, 1979; Bjartveit, 1997). The attendance in these
surveys in the mid-1970s was 85–90% and about 75% in the mid-
1990s (Bjartveit, 1997).
Deaths, emigrations and cases of thyroid cancer (International
Classification of Diseases, seventh revision (ICD-7): 194) in this
cohort were identified by linkage to the Death Registry at Statistics
Norway (Statistics Norway, 2006) and to the Cancer Registry of
Norway (The Cancer Registry of Norway, 2006). Both these
registries are population based and cover the entire Norwegian
population. A unique 11-digit identification number assigned to all
individuals living in Norway after 1960 facilitated the linkages.
The present study included only histologically verified thyroid
cancers. Persons with a diagnosis of thyroid cancer before the
height and weight measurements were excluded (n¼709). In the
analyses, the persons in the cohort were followed from the date of
measurement until the date of cancer diagnosis, emigration, age
100 years, death or until 31 December 2003. Altogether, 2001018
persons were eligible for the study. A small number of these (39
men and 32 women) were lost to follow-up.
Statistical methods
Cox’s proportional hazards regression models (Cox and Oakes,
1984), with time since measurement as the time variable, were
fitted to obtain relative risk estimates of cancer. In the analyses,
categorised variables for age at measurement, year of birth, BMI
((weight in kilograms)/(height in metres)
2) and height were
included. Body mass index was categorised using the WHO
categorisation (World Health Organization Consultation on
Obesity, 1998): BMI o18.5 (underweight), 18.5–24.9 (normal),
25.0–29.9 (preobese/overweight) and X30.0 kg/m
2 (obese).
Analyses were also performed treating BMI and height,
respectively, as continuous variables to test for trend in thyroid
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ycancer risk. Separate analyses were performed for papillary,
follicular, medullary, anaplastic, other carcinomas and other
malignant tumours. All these analyses were performed with the
statistical program package SPSS (SPSS Inc., SPSS for Windows,
Release 12.0.2.2004). The results were presented as relative risks
(RR) of cancer with 95% confidence intervals (CI). The hazard
functions of thyroid cancer by BMI and height in the Cox model
were estimated using spline functions in S-plus (Insightful
Corporation, 2002), with 4d.f.
RESULTS
The 2000947 persons (963523 men and 1037424 women)
included in this study were followed for on average 23 years
(maximum 41 years), constituting 47 million person-years
(Table 1). The mean age at measurement was 44 years, and the
proportions of obesity were 6 and 13% in men and women,
respectively. During follow-up, 3046 thyroid cancer cases were
diagnosed among the study subjects on average 15 years after the
measurements. The mean age at diagnosis was 62.2 and 57.7 years
in men and women, respectively.
The risk of thyroid cancer increased moderately by increasing
BMI in both sexes (Table 2). The RR of thyroid cancer per unit
increase in BMI was 1.03 (95% CI: 1.00–1.05) in men and 1.02
(95% CI: 1.01–1.03) in women. Excluding the first 5 years of
follow-up did not change these results. Splitting the upper BMI
category in women gave RRs of 1.27 (95% CI: 1.11–1.47), 1.33
(95% CI: 1.03–1.73) and 1.38 (95% CI: 0.83–2.30) with BMI of
30.0–34.9, 35.0–39.9 and 40 or above, respectively, compared with
normal-weighted women.
Histology-specific analyses revealed that the relative risk of
follicular carcinoma increased more than the risk of papillary
carcinoma with increasing BMI. Further, the risk of medullary
carcinoma tended to decrease with increasing BMI in both sexes,
being significant among females only. The RR of medullary
carcinoma per unit increase in BMI was 0.94 (95% CI: 0.85–1.04)
in men and 0.91 (95% CI: 0.86–0.97) in women. The number of
cases was low (52 and 107 medullary carcinomas in men and
women, respectively). The anaplastic carcinomas showed a strong
positive association with BMI in men.
The risk of thyroid cancer increased with increasing height in
both sexes (Table 2). The RR of thyroid cancer associated with
10cm increase in height was 1.18 (95% CI: 1.05–1.32) in men and
1.22 (95% CI: 1.13–1.31) in women.
Among males, the elevated risk associated with increased BMI
was confined to those measured at the age of 50–74 years
(Table 3).
Table 1 Number of observed cases of thyroid cancer, person-years and overall incidence rates
Men Women
Variable No. of cases Person-years Incidence rate
a No. of cases Person-years Incidence rate
a
Time since measurement
0–4 111 4703991 2 373 5101421 7
5–9 129 4185673 3 408 4626652 9
10–14 138 3538321 4 388 4037840 10
15–19 117 2973578 4 380 3549515 11
20–24 115 2513972 5 302 3129190 10
25–29 110 2099195 5 254 2710836 9
X30 58 1537708 4 163 2154886 8
Age at measurement
20–29 102 4857330 2 424 5592525 8
30–39 125 4646552 3 445 5274591 8
40–49 249 6527602 4 585 7032741 8
50–59 181 3457135 5 471 4461529 11
60–69 103 1702823 6 279 2421213 12
70–74 18 360996 5 64 527742 12
Year of birth
o1900 23 468282 5 71 685680 10
1900–1909 103 1775347 6 290 2553276 11
1910–1919 191 3513545 5 478 4548443 11
1920–1929 200 4993652 4 491 5567701 9
1930–1939 119 4316383 3 379 4830007 8
1940–1949 108 4645330 2 411 5106836 8
X1950 34 1839899 2 148 2018398 7
BMI (kg/m
2)
o18.5 2 138637 1 30 549113 5
18.5–24.9 412 12572703 3 1187 14418940 8
25.0–29.9 322 7837913 4 710 7426823 10
X30.0 42 1003185 4 341 2915463 12
Height (cm)
b
o150 28 366766 8
o160/150–159 8 143556 6 628 7042763 9
160–169 116 3323324 3 1,247 14591487 9
170–179/X170 429 11760603 4 365 3309325 11
X180 225 6324955 4
Total 778 21552438 4 2268 25310340 9
Abbreviations: BMI¼body mass index.
aNumber of thyroid cancer cases per 100000 person-years.
bSplit categories pertain to men and women, respectively.
BMI in relation to thyroid cancer
A Engeland et al
367
British Journal of Cancer (2006) 95(3), 366–370 & 2006 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yTable 2 RR of thyroid cancer with 95% CI obtained in Cox’s regression analyses; age at measurements and birth cohort were included in the model in
addition to either BMI or height
a
Papillary carcinoma Follicular carcinoma Medullary carcinoma Anaplastic carcinoma All thyroid cancers
Sex Variable RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Men 479 cases 111 cases 52 cases 54 cases 778 cases
BMI (kg/m
2)
o18.5 0.36 0.05–2.60 0.00 0.00-N 0.00 0.00-N 0.00 0.00-N 0.47 0.12–1.87
18.5–24.9 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.0–29.9 1.14 0.94–1.38 1.08 0.73–1.61 0.81 0.45–1.45 1.53 0.87–2.69 1.12 0.97–1.30
X30.0 1.11 0.73–1.69 1.66 0.82–3.37 0.69 0.16–2.91 2.33 0.88–6.20 1.14 0.82–1.56
Test for trend
b Height (cm) P¼0.05 P¼0.05 P¼0.3 P¼0.03 P¼0.03
o160 1.50 0.61–3.64 0.00 0.00-N 2.45 0.33–18 1.88 0.25–14 1.24 0.61–2.49
160–169 0.82 0.62–1.08 0.68 0.40–1.16 1.01 0.47–2.17 0.95 0.47–1.90 0.81 0.66–1.00
170–179 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
X180 1.29 1.06–1.59 1.02 0.65–1.61 1.22 0.64–2.32 0.78 0.38–1.61 1.17 0.99–1.38
Test for trend
b P¼0.001 P¼0.5 P¼0.5 P¼0.4 P¼0.005
Women 1456 cases 421 cases 84 cases 107 cases 2268 cases
BMI (kg/m
2)
o18.5 0.59 0.38–0.94 1.02 0.48–2.17 0.00 0.00-N 3.02 0.93–9.80 0.68 0.47–0.98
18.5–24.9 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.0–29.9 1.12 0.99–1.27 1.13 0.90–1.42 0.43 0.25–0.74 1.24 0.79–1.95 1.08 0.98–1.20
X30.0 1.19 1.01–1.41 1.63 1.24–2.15 0.35 0.16–0.79 1.65 0.97–2.80 1.29 1.13–1.46
Test for trend
b Height (cm) P¼0.008 P¼0.002 P¼0.004 P¼0.3 Po0.001
o150 0.76 0.45–1.27 1.09 0.54–2.23 0.00 0.00-N 0.30 0.04–2.16 0.76 0.52–1.11
150–159 0.92 0.81–1.05 1.07 0.86–1.34 0.98 0.59–1.63 0.56 0.36–0.89 0.95 0.86–1.05
160–169 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
X170 1.37 1.19–1.58 1.34 0.99–1.80 2.78 1.57–4.91 1.33 0.71–2.49 1.40 1.24–1.58
Test for trend
b Po0.001 P¼0.2 P¼0.01 P¼0.001 Po0.001
Abbreviations:BMI¼body mass index, CI¼confidence interval, RR¼relative risk.
aYear of birth and age at measurement were included as continuous variables when number of
cases was less than 150.
bBMI and height, respectively, were included as continuous variables.
Table 3 RR of thyroid cancer with 95% CI obtained in Cox’s regression analyses; age at measurements and birth cohort were included in the model in
addition to either body mass index or height. Analysis stratified on age at measurement
Thyroid cancer
Aged 20–49 years Aged 50–74 years
RR 95% CI RR 95% CI
Men 476 cases 302 cases
BMI (kg/m
2)
o18.5 0.37 0.05–2.67 0.61 0.09–4.36
18.5–24.9 1.00 Referent 1.00 Referent
25.0–29.9 1.08 0.89–1.30 1.20 0.95–1.52
X30.0 0.99 0.61–1.60 1.29 0.84–2.00
Test for trend
a P¼0.2 P¼0.09
Height (cm)
o160 1.05 0.26–4.21 1.29 0.57–2.92
160–169 0.88 0.65–1.20 0.76 0.58–1.01
170–179 1.00 Referent 1.00 Referent
X180 1.17 0.96–1.42 1.19 0.87–1.62
Test for trend
a P¼0.06 P¼0.03
Women 1,454 cases 814 cases
BMI (kg/m
2)
o18.5 0.63 0.42–0.94 1.03 0.46–2.31
18.5–24.9 1.00 Referent 1.00 Referent
25.0–29.9 1.10 0.97–1.25 1.07 0.91–1.25
X30.0 1.25 1.04–1.51 1.31 1.09–1.57
Test for trend
a P¼0.04 P¼0.001
Height (cm)
o150 0.95 0.51–1.77 0.70 0.44–1.13
150–159 0.91 0.79–1.04 1.00 0.87–1.16
160–169 1.00 Referent 1.00 Referent
X170 1.34 1.18–1.53 1.67 1.26–2.21
Test for trend
a Po0.001 P¼0.002
Abbreviations:BMI¼body mass index, CI¼confidence interval, RR¼relative risk.
aBMI and height, respectively, were included as continuous variables.
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thyroid cancer in women are illustrated in Figure 1. The risk of
thyroid cancer increased with increasing height and BMI above
25kg/m
2.
DISCUSSION
In this large cohort, including more than two million individuals,
we explored the associations between BMI and height and the
occurrence of thyroid cancer. The risk was found to be moderately
elevated with increasing BMI and height in both sexes among the
follicle-cell derived (papillary and follicular) carcinomas. In
medullary carcinomas, an opposite trend was present for BMI,
pointing to a different pathogenetic influence.
The associations between BMI and height with thyroid cancer
have been difficult to explore in previous small studies owing to
the low incidence of this disease. In addition to the large size of the
present cohort, we also had an almost complete follow-up with
regard to thyroid cancer incidence and deaths. This was made
possible by linkages to population-based registries of high quality.
Only 0.04% of the study cohort (71 persons) was lost to follow-up,
and 0.6% was censored by emigration from Norway.
After a pooled analysis of 12 case–control studies, including
2473 cases, Dal Maso et al (2000) previously found a moderately
increased risk of thyroid cancer related to height and weight at
diagnosis. Dal Maso et al (2000) used self-reported values for
height and weight during the late teens and at diagnosis. In the
present study, we relied on height and weight measurements
performed on average 15 years before the diagnosis of thyroid
cancer. Hence, our estimates were not diluted by a possible
influence of individuals weight on the disease.
Iribarren et al (2001) evaluated several potential predictors
of thyroid cancer in a large American cohort with long
follow-up, including more than 200000 persons. Despite the
large size of the cohort and the long follow-up, only 196
thyroid cancers were observed. In this study, no association
between BMI, height or weight gain and thyroid cancer was
observed.
Dal Maso et al (2000) hypothesised that an association
between BMI and thyroid cancer could be owing to a relation-
ship with steroid hormones or other endocrine factors.
However, they observed an association between BMI and thyroid
cancer of similar magnitude in older and younger women.
Also in the present study, there was no difference in the
association between BMI and thyroid cancer in older and younger
women.
Like Dal Maso et al (2000), we observed a moderately increasing
risk of thyroid cancer with increasing height. This association may
be owing to dietary influence during childhood or adolescence and
possible interactions with growth factors.
In conclusion, the present study showed that the risk of thyroid
cancer increased moderately with increasing BMI and height in
both males and females.
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